All News
Filter News
Found 808,690 articles
-
Cognito Therapeutics Raises $73M Series B to Advance Neurotechnology Platform for Alzheimer’s Disease
3/22/2023
Cognito Therapeutics announced today a $73M Series B financing round led by FoundersX Ventures with participation from all existing investors.
-
Massive Bio and NeoGenomics Announce Collaboration to Accelerate Oncology Drug Discovery and Improve Patient Care
3/22/2023
Massive Bio, Inc. and NeoGenomics, Inc. today announced a collaboration with the goal of accelerating the development of new cancer therapies and ultimately improving the lives of millions of cancer patients around the world.
-
Jacobio Pharma Announces 2022 Annual Results
3/22/2023
Jacobio Pharma (1167.HK) announced its 2022 annual results. R&D investment was RMB530 million , showing an increase of 26% compared with 2021.
-
Astria Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate Update
3/22/2023
Astria Therapeutics today reported financial results for the fourth quarter and full year ended December 31, 2022 and provided a corporate update.
-
JanOne Sells Legacy Business ARCA Recycling to Concentrate on Growing BioPharm Businesses
3/22/2023
JanOne announced that on March 9, 2023 they entered into a Stock Purchase Agreement with VM7, a Delaware corporation, under which VM7 agreed to acquire all of the outstanding equity interests of ARCA Recycling, Inc, Customer Connexx LLC and ARCA Canada Inc. Virland Johnson, who has served as ARCA Recycling's CFO and COO for several years is the principal of VM7.
-
Amryt Pharma Shareholders approve acquisition of Amryt Pharma by Chiesi Farmaceutici
3/22/2023
Amryt Pharma Shareholders approve acquisition of Amryt Pharma by Chiesi Farmaceutici.
-
TC Biopharm Announces Corporate Restructuring, Reduction in Overhead
3/22/2023
TC BioPharm PLC announced a corporate restructuring plan to reduce costs and prioritize its pending lead US clinical programs.
-
Pressure BioSciences Receives $1.5M Contract for UltraShear Nanoemulsified CBD
3/22/2023
Pressure BioSciences, Inc. today announced the execution and launch of a manufacturing and distribution agreement (the "Agreement").
-
Gilead Sciences Announces $3 Million in Grant Funding to Eight Organizations Addressing HIV Disparities in Rural U.S. Communities
3/22/2023
Gilead Sciences, Inc. (Nasdaq: GILD) today announced it is providing a total of $3 million in grant funding to eight organizations to provide services to communities disproportionately impacted by HIV in rural areas in the United States.
-
Ascentage Pharma Announces 2022 Annual Results Including Strong Sales of Olverembatinib and Steady Progress in Transition Towards Biopharma
3/22/2023
Ascentage Pharma today announced its annual results for the full year 2022.
-
Marker Therapeutics Reports Fiscal Year 2022 Corporate and Financial Results
3/22/2023
Marker Therapeutics, Inc. today reported fiscal year 2022 financial results and provided updates for its clinical development programs.
-
Truveta and Alpine Immune Sciences Announce Strategic Partnership to Access Truveta’s Community to Accelerate Recruitment to Povetacicept Clinical Trials
3/22/2023
Today, Truveta and Alpine Immune Sciences, Inc. (NASDAQ: ALPN) announced a strategic partnership to help accelerate clinical trial recruitment for povetacicept, Alpine’s dual B cell cytokine antagonist being developed for multiple B cell-mediated autoimmune and inflammatory diseases.
-
Visus Therapeutics Completes Enrollment in BRIO-I, a Phase 3 Clinical Trial of BRIMOCHOL™ PF for the Treatment of Presbyopia
3/22/2023
Visus Therapeutics Completes Enrollment in BRIO-I, a Phase 3 Clinical Trial of BRIMOCHOL ™ PF for the Treatment of Presbyopia.
-
Ancora Heart’s AccuCinch System Demonstrates Significant Improvement in Quality of Life, Cardiac Structure and Function in Heart Failure Patients
3/22/2023
Ancora Heart, Inc today announced that patients treated with the investigational AccuCinch ® Ventricular Restoration System demonstrated improvement in HF patient outcomes and beneficial changes in the structure of the heart.
-
Spectrum Pharmaceuticals Reports Fourth Quarter 2022 and Full Year 2022 Financial Results and Corporate Update
3/22/2023
Spectrum Pharmaceuticals, Inc. announced today financial results for the three-month period and full year ended December 31, 2022.
-
Alzamend Neuro Announces Completion of Clinical Portion of Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s
3/22/2023
Alzamend Neuro, Inc. today announced the completion of the clinical portion of its Phase IIA multiple ascending dose (“ MAD ”) study for dementia related to Alzheimer’s.
-
FDA Expands Indications for Use of FibroScan® for Comprehensive Liver Management
3/22/2023
The U.S. Food and Drug Administration (FDA) has cleared expanded Indications for Use for screening with FibroScan®, the non-invasive liver management technology by Echosens.
-
EpiBiologics Launches with $50 million Series A Financing to Advance Next-Generation Protein Degradation Platform
3/22/2023
EpiBiologics launched today with $50 million in Series A funding.
-
DermBiont Presents Positive Phase 2 Trial Data Treating Seborrheic Keratosis with SM-020 Topical Gel at American Academy of Dermatology Annual Meeting
3/22/2023
DermBiont today announced that its Phase 2 adaptive design trial with of investigational drug SM-020 gel 1.0% met its primary endpoint of a one point improvement in Physician’s lesion assessment (PLA) score at last visit and safety via local tolerability, as well as key multiple secondary endpoints including complete clearance of treated lesions.
-
European Commission Grants Orphan Designation for iECURE’s Lead Product Candidate GTP-506 for the Treatment of Ornithine Transcarbamylase (OTC) Deficiency
3/22/2023
iECURE announced today that the European Commission granted orphan designation for the company’s lead product candidate GTP-506 for the treatment of Ornithine Transcarbamylase (OTC) deficiency.